Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.

@article{Hershman2014PreventionAM,
  title={Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.},
  author={Dawn L. Hershman and Christina Lacchetti and Robert H. Dworkin and Ellen M. Lavoie Smith and Jonathan S Bleeker and Guido Cavaletti and Cynthia Chauhan and Patrick R. Gavin and Antoinette Lavino and Maryam B. Lustberg and Judith A Paice and Bryan Schneider and Mary Lou Smith and Tom Smith and Shelby A. Terstriep and Nina D. Wagner‐Johnston and Kate Bak and Charles L. Loprinzi},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2014},
  volume={32 18},
  pages={
          1941-67
        }
}
PURPOSE To provide evidence-based guidance on the optimum prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathies (CIPN) in adult cancer survivors. METHODS A systematic literature search identified relevant, randomized controlled trials (RCTs) for the treatment of CIPN. Primary outcomes included incidence and severity of neuropathy as measured by neurophysiologic changes, patient-reported outcomes, and quality of life. RESULTS A total of 48 RCTs… Expand

Paper Mentions

Interventional Clinical Trial
The proposed randomized control trial will evaluate auricular point acupressure (APA) on chemotherapy-induced neuropathy (CIN), rigorously considering point specificity and placebo… Expand
ConditionsChemotherapy-induced Neuropathy
InterventionDevice, Other
Interventional Clinical Trial
The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to the clinical management of patients with pain… Expand
ConditionsChemotherapy-induced Peripheral Neuropathy, Pain, Neuropathic, Pain Syndrome
InterventionDrug
Interventional Clinical Trial
Chemotherapy cause many adverse events including induction of peripheral neuropathy. Metformin, the AMPK activator, was found to have protective effect against chemotherapy… Expand
ConditionsChemotherapy-induced Peripheral Neuropathy
InterventionDrug
Interventional Clinical Trial
The aim of the study is to evaluate the effect of intravenous (IV) lidocaine versus oral duloxetine on the onset and severity of TIPN in patient with breast cancer as well as… Expand
ConditionsBreast Cancer, Chemotherapy-induced Peripheral Neuropathy, Peripheral Neuropathy
InterventionDrug
Treatment of Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Recommendations.
TLDR
A systematic review of each treatment regimen in patients with CIPN found duloxetine was considered of moderate benefit and Photobiomodulation, known as low level laser therapy, is considered ofmoderate benefit based on the evidence review. Expand
Chemotherapy-induced peripheral neuropathy clinical trials
TLDR
These data identify reporting practices that could be improved in order to enhance readers' ability to critically evaluate RCTs of CIPN treatments and use the findings to inform the design of future studies and clinical practice. Expand
Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.
  • J. Paice, R. Portenoy, +13 authors E. Bruera
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
TLDR
An ASCO-convened expert panel conducted a systematic literature search of studies investigating chronic pain management in cancer survivors to provide evidence-based guidance on the optimum management of chronic pain in adult cancer survivors. Expand
Instruments for Assessing Chemotherapy-Induced Peripheral Neuropathy: A Review of the Literature.
TLDR
This review is designed to identify valid and reliable assessment tools that measure or assess CIPN in adult patients receiving chemotherapy and finds no consensus exists on the most appropriate patient self-report scale for use in the general oncology population. Expand
Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge.
TLDR
A critical overview of pediatric CIPN, its incidence, clinical manifestations, late effects, and recent advances in understanding of risk factors and pharmacogenomics as well as evaluating current assessment strategies and treatment approaches is provided. Expand
Exercise Effects on Chemotherapy-Induced Peripheral Neuropathy
TLDR
The empirical evidence is insufficient to definitively conclude that exercise interventions ameliorate CIPN, but aerobic exercise may be a key component of exercise interventions for CIPn. Expand
The Relationship of Chemotherapy-Induced Peripheral Neuropathy and Obesity: A Systematic Review
  • M. Jesse
  • Medicine
  • Rehabilitation Oncology
  • 2019
TLDR
Being overweight or obese would put one at a higher risk for development of CIPN, and Clinicians should encourage healthy lifestyles to help decrease or control symptoms and/or limit dose reductions of chemotherapy. Expand
National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons
TLDR
Current inquiry is being guided by the results from these large-scale trials, and stands better chance of identifying durable solutions for this treatment-limiting toxicity. Expand
Trial designs for chemotherapy-induced peripheral neuropathy prevention
TLDR
It is hoped that attention to the design considerations and recommendations outlined in this article will improve the quality and assay sensitivity of CIPN prevention trials and thereby accelerate the identification of efficacious therapies. Expand
NCI Clinical Trials Planning Meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy.
TLDR
The results of the CTPM provide support for conducting clinical trials that include both pharmacological and non-pharmacological approaches, alone or in combination, with biomarkers, genetics or other measures designed to inform underlying CIPN mechanisms. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 108 REFERENCES
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.
TLDR
Good validity and reliability scores were demonstrated for the set of selected impairment and quality-of-life outcome measures in CIPN and future studies are planned to investigate the responsiveness aspects of these measures. Expand
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients
TLDR
High-grade OXA neurotoxicity can be predicted by clinical and neurophysiological information obtained at mid-treatment and Neurological assessment of acute neuropathy symptoms and radial and dorsal sural nerves NCS should be carefully monitored to predict and hopefully prevent the induction of severe OxAIPN. Expand
The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial
TLDR
Vitamin E did not appear to reduce the incidence of sensory neuropathy in the studied group of patients receiving neurotoxic chemotherapy, and the treatment was well tolerated overall. Expand
Impact of oxaliplatin-induced neuropathy: a patient perspective
TLDR
The monitoring of oxaliplatin-induced neurotoxicity would benefit from more informative clinical assessment, with inclusion of patient-reported outcome measures, in a clinical trial setting to monitor the efficacy of interventions and in prospective studies of survivorship. Expand
Measures of chemotherapy‐induced peripheral neuropathy: a systematic review of psychometric properties
TLDR
Two measures emerged as potentially useful for clinical trials and patient care, including the FACT/GOG‐Ntx, which is a subjective measure of CIPN‐related quality of life (QoL) and the TNS clinical versions which incorporate both subjective measures and objective examinations of nerve function. Expand
Chemotherapy‐Induced Peripheral Neuropathy: Prevention and Treatment
TLDR
Agents with the strongest supporting evidence for efficacy in the treatment of CIPN include topical pain relievers, and serotonin and norepinephrine reuptake inhibitors, such as venlafaxine and duloxetine. Expand
Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy
TLDR
The FACT/GOG-Ntx is an appropriate outcome measure for clinical trials evaluating ways to prevent long-term neurotoxicity in BC survivors and changes in hand/foot numbness/discomfort were significantly associated with change in vibration threshold. Expand
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools.
TLDR
In this review, the available data regarding the different tools used to assess CIPN will be revised and their features will be critically examined, with a special focus on their reliability and reproducibility across examiners and, when available, through direct comparison. Expand
Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer.
TLDR
Oncologists limited the dosing of chemotherapy because of CIPN in a significant proportion of paclitaxel recipients, most frequently in those who received a weekly regimen. Expand
NCCN task force report: management of neuropathy in cancer.
TLDR
This report documents the proceedings of this meeting with a general background on neuropathy and neuropathy in oncology, followed by discussions on challenges and research issues, evaluation criteria, and management of different symptoms associated with this disorder. Expand
...
1
2
3
4
5
...